Iovance Biotherapeutics and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License Agreement

NEXT STORY
Ascendis Pharma A/S Provides Pipeline Update and Reviews Progress Towards Vision 3×3 at 38th Annual J.P. Morgan Healthcare Conference
PREV STORY
Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the Atlantic Coast Retina Club Macula 20/20 Annual Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Iovance Biotherapeutics and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License Agreement

NEXT STORY
Ascendis Pharma A/S Provides Pipeline Update and Reviews Progress Towards Vision 3×3 at 38th Annual J.P. Morgan Healthcare Conference
PREV STORY
Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the Atlantic Coast Retina Club Macula 20/20 Annual Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

New interim data demonstrate Sandoz proposed biosimilar rituximab has equivalent efficacy to reference product

ASSIST-FL trial demonstrates equivalent safety, efficacy, pharmacokinetics and pharmacodynamics of Sandoz proposed biosimilar rituximab ...

author_avatar
NASDAQ Market News

BeiGene Presents Initial Phase 1 Data on Anti-PD-1 Antibody BGB-A317 Combined with PARP Inhibitor BGB-290 at the 2017 American Society for Clinical Oncology Annual Meeting

CAMBRIDGE, Mass., June 05, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical ...

author_avatar
NASDAQ Market News

CorMedix Inc. to Present at the 20th Annual Needham Virtual Healthcare Conference

author_avatar
NASDAQ Market News